Literature DB >> 25832305

Quality compared to quantity of life in laryngeal cancer: A time trade-off study.

David W Hamilton1, Janneke E Bins2, Peter McMeekin1, Ami Pedersen3, Nicholas Steen1, Anthony De Soyza4,5, Richard Thomson1, Vinidh Paleri3, Janet A Wilson3.   

Abstract

BACKGROUND: The purpose of this study was to use time trade-off to assess the factors influencing patients' decisions in advanced laryngeal cancer. Time trade-off is a well-established method of assessing how individuals value a particular health state.
METHODS: We developed vignettes depicting life after chemoradiotherapy or laryngectomy. One hundred fourteen participants ranked them, assigned utility values, and rated the importance of survival on treatment choice.
RESULTS: Chemoradiotherapy was preferred by 62% and laryngectomy by 38%. Chemoradiotherapy optimal outcome had the highest mean utility value (0.64) followed by total laryngectomy optimal outcome (0.56). Total laryngectomy poor outcome (0.33) was equivalent to chemoradiotherapy poor outcome (0.32).The average survival advantage required for a participant to change their preferred choice was 2.1 years.
CONCLUSION: The functional treatment outcome had a greater effect on health state utility values than treatment modality. In many individuals, larynx conservation may not be the primary consideration in treatment preference.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E631-E637, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemoradiotherapy; head and neck neoplasms; laryngeal neoplasms; laryngectomy; larynx

Mesh:

Year:  2015        PMID: 25832305     DOI: 10.1002/hed.24061

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

2.  Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Michael Hoerger; Graceanne R Wayser; Gregory Schwing; Ayako Suzuki; Laura M Perry
Journal:  Ann Behav Med       Date:  2019-06-04

3.  Health-related quality of life and utility in head and neck cancer survivors.

Authors:  Li-Jen Liao; Wan-Lun Hsu; Wu-Chia Lo; Po-Wen Cheng; Pei-Wei Shueng; Chen-Hsi Hsieh
Journal:  BMC Cancer       Date:  2019-05-07       Impact factor: 4.430

4.  Effect of comprehensive nursing intervention in preventing postoperative pain, complications, and psychological pressure in the otolaryngology department.

Authors:  Rong-Lan Luan; Ming-Xia Zhu; Hai-Yan Sun
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

5.  Utility Outcome Measures for the Treatment of Ameloblastomas during Childhood.

Authors:  Constanta David; Johnny I Efanov; Daniel E Borsuk
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-01-22

6.  How do patients make decisions in the context of a multidisciplinary team: an ethnographic study of four head and neck cancer centres in the north of England.

Authors:  David Winston Hamilton; Benjamin Heaven; Richard Thomson; Janet Wilson; Catherine Exley
Journal:  BMJ Open       Date:  2022-08-24       Impact factor: 3.006

Review 7.  A systematic literature review of health state utility values in head and neck cancer.

Authors:  Michela Meregaglia; John Cairns
Journal:  Health Qual Life Outcomes       Date:  2017-09-02       Impact factor: 3.186

8.  Integrin β1 regulates the invasion and radioresistance of laryngeal cancer cells by targeting CD147.

Authors:  Li Li; Xiaoxia Dong; Feng Peng; Li Shen
Journal:  Cancer Cell Int       Date:  2018-06-07       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.